From today's Times:

Tiddler to watch

"ImmuPharma, steady at 46p, the biotech group which has a treatment of the disease Lupus in phase II trials, could benefit from the failure this week of trials of rival drug Rituxan. ImmuPharma's housebroker, Panmure Gordon, believes its client may attract the attention of Rituxan's developers, Genentech and Biogen Idec."

OK, I know we're all heartily sick of the promising small pharmacos, but I thought I'd bring this one to your attention because the demise of one much-hyped drug can indeed have a positive knock-on effect elsewhere. Furthermore, there doesn't seem to be much medication out there for Lupus.

This company is run by experienced people who have previously worked for some of the majors like GSK, Bristol-Myers Squibb, etc, and in investment banking. Their research results have been positive so far.

I made a good profit on these last year and the sp seems to have turned up again recently. Bought back again this morning. (NB: too small to trade in CFDs)

ImmuPharma to present Lupuzor data later this month
8:15 am by Ian LyallImmuPharma is currently looking for a partner to take Lupuzor into the final phase of clinical trials.



ImmuPharma (LON:IMM) confirmed this morning that it will present data on its lead drug candidate Lupuzor to the prestigious annual American College of Rheumatology meeting later this month.

The ACR recently confirmed it had accepted the group’s abstract paper on phase IIb data from the Lupuzor trial.

The presentation will be given on November 14 by ImmuPharma’s chief scientific officer Robert Zimmer and Professor Daniel Wallace of the Cedars-Sinai Medical Centre in Los Angeles, a leading authority on Lupus.

Lupuzor was developed to treat the chronic autoimmune disease Lupus and has blockbuster potential.

It has also been given fast-track designation by America’s all-powerful Food & Drug Administration.

The company is currently looking for a partner to take Lupuzor into the final phase of clinical trials.

sp likely to go to sleep until the results of the lupuzor trials become imminent
given the likely high volatility, i have just sold the balance of my trading position at 130 for a modest profit, but shall retain the medium stake in my sipp

All looking good here imo
Can't believe how little posting goes on here. Have been in since 88p days so am happy with current performance. Will hold for the results of the trials..could be big gains to be made but all very speculative. dyor etc but GLA!

IMM
PI's excluded (shafted) yet again!

ImmuPharma raises £10m
Specialist drug discovery and development company ImmuPharma has raised £10m, gross, through a placing of 6,944,445 new ordinary shares at 144p apiece with new and existing investors


explains the weakness of sp over the last few days
that said, the placing was at 144 which is at only a very small discount

IMM has been clattered today by about 18% on the back of the following .....

Tim McCarthy, the Company's Non-executive Chairman (IMM), is currently on the board of Harvard Healthcare Limited ("Harvard"). On 5 March 2018 the Directors of Harvard passed a board resolution following which Harvard will be placed into a Creditors' Voluntary


however, i do not see the direct relevance to IMM
is there something i have missed?

160p to close the gap anybody?

Gap closed intra-day.

All looking good so far imvho. GLA

Lupuzor™ demonstrated a superior response rate over placebo* (52.5% vs 44.6% "responders"**) in the primary analysis on the Full Analysis Set of all 202 patients (including withdrawals who are considered non-responders). However, due to a high response rate in the placebo group, this superior response did not allow statistical significance to be reached (p = 0.2631) and the trial's primary end point was not met.

===============

OUCH!
serves me right but fortunately not too many
is there now anything left in this company top sell?
if they're lucky, they may be taken out by a bigger fish